Evaluation of Therapeutic Efficacy of Faricimab for Clinical AMD, DME, and RVO Patients

Phase 2

Recruiting

• Conditions: Age-Related Macular Degeneration; Diabetic Macular Edema; Retinal Vein Occlusion

• Registration Number: NCT06572553
• Lead Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-8-13
• Last Update Posted: 2 September 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Inclusion Criteria:<br><br> 1. Chinese patients aged 18 years or older and of any gender;<br><br> 2. Patients who have been diagnosed with nAMD, DME or RVO by OCT, FFA, ICGA or OCTA;<br><br> 3. Patients whose decision to receive treatment with faricimab was made prior to and<br> independent of study participation;<br><br> 4. Patients who have received at least one treatment with faricimab during the course<br> of the study;<br><br> 5. have signed an informed consent form.<br><br>Exclusion Criteria:<br><br> 1. Active ocular inflammation or suspected active ocular infection in either eye;<br><br> 2. Receipt of any other anti-VEGF therapy after faricimab;<br><br> 3. Patient is unable to provide clinical data (visual acuity and OCT images) within 2<br> weeks (14 days) prior to receiving the initial faricimab injection;<br><br> 4. Currently participating in any other clinical trial.

Exclusion Criteria

Not provided

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Best Corrected Visual Acuity (BCVA)

Secondary Outcome Measures

Name	Time	Method
central retinal thickness (CRT);Choroidal neovascularization (CNV)